Home/Filings/4/0001209191-17-025793
4//SEC Filing

Epizyme, Inc. 4

Accession 0001209191-17-025793

CIK 0001571498operating

Filed

Apr 4, 8:00 PM ET

Accepted

Apr 5, 5:44 PM ET

Size

15.0 KB

Accession

0001209191-17-025793

Insider Transaction Report

Form 4
Period: 2017-04-04
Copeland Robert A
EVP and CSO10% Owner
Transactions
  • Exercise/Conversion

    Commons Stock, par value $0.0001

    2017-04-04$2.19/sh+2,000$4,38033,538 total
  • Exercise/Conversion

    Commons Stock, par value $0.0001

    2017-04-04$3.54/sh+3,000$10,62036,538 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2017-04-042,0000 total
    Exercise: $2.19Exp: 2022-10-02Common Stock (2,000 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2017-04-043,00043,550 total
    Exercise: $3.54Exp: 2023-01-24Common Stock (3,000 underlying)
  • Sale

    Commons Stock, par value $0.0001

    2017-04-04$16.36/sh2,500$40,89631,538 total
  • Sale

    Commons Stock, par value $0.0001

    2017-04-04$16.36/sh2,500$40,90934,038 total
Footnotes (4)
  • [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.35 per share to $16.50 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.35 per share to $16.40 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person.
  • [F4]This option is fully vested.

Issuer

Epizyme, Inc.

CIK 0001571498

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001571498

Filing Metadata

Form type
4
Filed
Apr 4, 8:00 PM ET
Accepted
Apr 5, 5:44 PM ET
Size
15.0 KB